PASG (Passage Bio) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 05, 2026)


PASG Passage Bio Inc PASG
30 GF Score
Price $4.63
! 2 Warning Signs
View Full Analysis

What is Passage Bio 5-Year Yield-on-Cost %?

Passage Bio PASG +2.18% 30 5-Year Yield-on-Cost % is 0.00 as of Jul. 05, 2026. GuruFocus rates PASG with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 153 Biotechnology companies, Passage Bio ranks worse than 653594.12% on this metric.

Passage Bio's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Passage Bio's 5-Year Yield-on-Cost % or its related term are showing as below:



PASG's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.64
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Passage Bio  (NAS:PASG) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Passage Bio 5-Year Yield-on-Cost % Related Terms


PASG vs CTXR, HIND, GTBP: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Passage Bio's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Passage Bio 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Passage Bio's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Passage Bio's 5-Year Yield-on-Cost % falls into.


PASG
30GF Score
Passage Bio Inc PASG
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Passage Bio 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Passage Bio is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Passage Bio (PASG) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 05, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Passage Bio and its competitors. According to the industry distribution chart, Passage Bio ranks #999999 out of 153 companies in the Biotechnology industry.
Is Passage Bio's 5-Year Yield-on-Cost % too high?
Passage Bio's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Passage Bio ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Passage Bio has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Passage Bio's 5-Year Yield-on-Cost % compare to CTXR and HIND?
According to the Biotechnology industry distribution chart, Passage Bio ranks #999999 out of 153 companies for 5-Year Yield-on-Cost %. This places Passage Bio in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.64, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Passage Bio and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Passage Bio's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Passage Bio stock overvalued right now?
Passage Bio (PASG) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Passage Bio's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Passage Bio (PASG), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Passage Bio Business Description

Address 2005 Market Street, 39th Floor, One Commerce Square, Philadelphia, PA, USA, 19103
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
30GF Score

Get the complete analysis for PASG

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.63
Price